WELL Health Technologies Corp. : The technical configuration is positive
Entry price | Target | Stop-loss | Potential |
---|
$7.32 |
$9.23 |
$6.36 |
+26.09% |
---|
The timing appears opportune to go long in shares of WELL Health Technologies Corp. as we anticipate another pick-up in the underlying trend.
Strengths● Graphically speaking, the timing seems perfect for purchasing the stock close to the CAD 7.5 support.
● Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
● For the past twelve months, EPS forecast has been revised upwards.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
● The tendency within the weekly time frame is positive above the technical support level at 4.85 CAD
Weaknesses● The company sustains low margins.
● With an expected P/E ratio at 152 and 43.25 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.